Absorbable bone wax and preparation method thereof
By using PCL/PEG copolymer and modified PLGA fiber to prepare absorbable bone wax, the problems of foreign body reaction caused by non-absorbable bone wax and unstable mechanical properties of absorbable bone wax were solved, and an absorbable bone wax material with good hemostatic effect was achieved to promote bone healing.
Patent Information
- Application Number
- CN202510841903.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-06-23
- Publication Date
- 2025-09-12
AI Technical Summary
Existing non-absorbable bone wax will cause foreign body reaction and inflammation when retained in the body for a long time, affecting bone tissue healing. Meanwhile, the mechanical properties of absorbable bone wax are unstable, which limits its application.
PCL/PEG copolymer and modified PLGA fiber were used as the main raw materials. Modified PLGA fiber was prepared by electrospinning technology. Regenerated oxidized cellulose and nano-hydroxyapatite were added as reinforcers to regulate the degradation rate and mechanical properties of the material, thereby improving the hemostatic and occlusive effects of bone wax.
The bone wax has stable mechanical properties and good sealing effect during hemostasis. It gradually degrades and is absorbed as the bone heals, does not affect the healing process, avoids secondary surgery, and has antibacterial properties.
Smart Images
Figure BDA0005462402530000071 
Figure BDA0005462402530000081
Abstract
Description
Technical Field
[0001] The present application relates to the technical field of hemostatic materials, and more specifically, to an absorbable bone wax and a preparation method thereof. Background Art
[0002] Bone wax can play a relatively important role in clinical practice. Common bone wax products are mainly made of non-absorbable materials, such as paraffin oil, paraffin and beeswax. Although these materials can effectively stop bleeding and prevent bone marrow fluid loss during surgery, long-term residues in the body may cause foreign body reactions, inflammation and other symptoms, affecting the regeneration and healing of bone tissue.
[0003] Non-absorbable bone wax is prone to foreign body reactions during use, and long-term retention in the body can lead to local inflammation, fibrous wrapping and other problems, affecting bone healing. Absorbable bone wax, such as polyethylene glycol, has unstable mechanical properties and is prone to insufficient strength during use, which limits its application. Summary of the Invention
[0004] In order to ensure the absorption effect of bone wax while improving the strength of absorbable bone wax, the present application provides an absorbable bone wax and a preparation method thereof.
[0005] In a first aspect, the present application provides an absorbable bone wax, which adopts the following technical solution: An absorbable bone wax comprises the following raw materials in parts by weight: 65-75 parts of PCL / PEG copolymer, 0.8-1.2 parts of sodium carboxymethyl cellulose, and 3.25-4.12 parts of modified PLGA fibers.
[0006] By adopting the above technical solution, the PCL / PEG copolymer has good hydrophilicity. At the same time, PCL can improve the mechanical strength of bone wax. The addition of modified PLGA fibers can further improve the mechanical properties of bone wax, making the bone wax less likely to break or fracture during plasticity and use, and making the mechanical properties of bone wax relatively stable. Sodium carboxymethyl cellulose can increase the viscosity of bone wax. At the same time, the PCL / PEG copolymer and modified PLGA fibers are human-absorbable and degradable materials. By adjusting the raw material ratio of PCL / PEG copolymer and PLGA, their degradation rate can be effectively controlled, thereby changing the degradation cycle of bone wax in the human body. PEG can accelerate the degradation cycle of PCL / PEG copolymer in the human body. PLGA improves the mechanical properties and occlusive effect of bone wax in the early stage of hemostasis. As hemostasis is completed, it is first hydrolyzed, increasing the porosity of bone wax and promoting the hydrolysis of PCL / PEG copolymer. PCL / PEG copolymer, sodium carboxymethyl cellulose and modified PLGA fibers can be degraded and absorbed by the human body in the late stage of bone healing. The mechanical properties and bonding strength during use and hemostasis are good, and secondary surgery is not required for removal, as the bone wax is naturally absorbed through human metabolism.
[0007] Preferably, the preparation method of the PCL / PEG copolymer comprises the following steps: mixing sodium hydride, PEG and caprolactone, stirring until the caprolactone reacts completely, heating to 65°C, keeping warm and stirring for 20 minutes, adding excess chloroform to dissolve, performing rotary evaporation, adding ether to precipitate, and filtering to obtain the PCL / PEG copolymer.
[0008] By adopting the above technical solution and using sodium hydride as a catalyst, PEG and caprolactone are copolymerized to form a PCL / PEG copolymer, which improves the hydrophilicity of PCL while ensuring the mechanical properties of the PCL / PEG copolymer.
[0009] Preferably, the preparation method of the modified PLGA fiber comprises the following steps: dissolving PLGA in chloroform to prepare a spinning solution, adding a reinforcing modifier to the spinning solution, stirring and shaking to uniformly disperse the reinforcing modifier, and then performing electrostatic spinning to obtain the modified PLGA fiber.
[0010] By adopting the above technical solution, PLGA fibers are prepared by electrospinning, and reinforcing modifiers are added to the PLGA fibers, so that the mechanical properties of the modified PLGA fibers are improved. At the same time, the reinforcing modifiers are made of degradable and absorbable materials, which further improves the mechanical stability of bone wax without affecting the degradation and absorption of bone wax.
[0011] Preferably, the reinforcing modifier is regenerated oxidized cellulose and nano-hydroxyapatite, and the amount of the reinforcing modifier added to the spinning solution is 11.25-15.35 wt%.
[0012] By adopting the above technical solution, regenerated oxidized cellulose and nano-hydroxyapatite are compounded. The regenerated oxidized cellulose can improve the hemostatic performance of bone wax and has an antibacterial effect. The combined use of regenerated oxidized cellulose and nano-hydroxyapatite can maintain the strength of the modified PLGA fiber while improving the hemostatic effect of bone wax, thereby improving the mechanical strength of bone wax.
[0013] Preferably, the mass ratio of the regenerated oxidized cellulose to the nano-hydroxyapatite is (1.26-1.35):(2.15-2.94).
[0014] By adopting the above technical solution, the mass ratio of regenerated oxidized cellulose and nano-hydroxyapatite is controlled. If the content of regenerated oxidized cellulose is too high, the strength of the modified PLGA fiber will drop significantly after absorbing water, which is not conducive to maintaining the mechanical strength of bone wax. If the content of nano-hydroxyapatite is too high, the brittleness of the modified PLGA fiber will increase, which is not conducive to the shaping and use of bone wax.
[0015] Preferably, the nano-hydroxyapatite is further treated as follows before being added: the nano-hydroxyapatite is dispersed in a nitric acid solution, ultrasonicated for 30 minutes, washed, dried and set aside, the silane coupling agent is mixed with an ethanol solution, stirred for 1 hour to prepare a mixed solution, the treated nano-hydroxyapatite is dispersed in the mixed solution, magnetically stirred at 60-70°C for 4-6 hours, washed and dried.
[0016] By adopting the above technical solution, nano-hydroxyapatite is treated with a silane coupling agent, thereby effectively improving the dispersibility of nano-hydroxyapatite in the spinning solution, while facilitating the combination of nano-hydroxyapatite with regenerated oxidized cellulose and modified PLGA fibers, and improving the uniformity and strength of the modified PLGA fibers.
[0017] Preferably, the electrospinning conditions are: spinning rate of 0.4 mL / h, spinning voltage of 1.5 kV, receiving distance of 15 cm, and spinning diameter of 0.15-0.3 mm.
[0018] By adopting the above technical solution and controlling the conditions of electrostatic spinning, the diameter of the modified PLGA fibers obtained by spinning is moderate and uniform.
[0019] In a second aspect, the present application provides a method for preparing absorbable bone wax, which adopts the following technical solution: A method for preparing absorbable bone wax comprises the following steps: dispersing PCL / PEG copolymer in water, uniformly dispersing modified PLGA fibers by ultrasonication, removing bubbles, freeze-drying and molding to obtain the absorbable bone wax.
[0020] By adopting the above technical solution, the absorbable bone wax prepared is easy to shape, has a better hemostatic effect after use, and has good mechanical properties and adhesion. The mechanical properties during use are relatively stable, providing good hemostatic and sealing effects for bone wounds, and degrading and being absorbed by the human body as the bone heals, without the need for a secondary operation to remove it.
[0021] In summary, this application has the following beneficial effects: 1. In the present application, the PCL / PEG copolymer has good hydrophilicity, and PCL can improve the mechanical strength of bone wax. The addition of modified PLGA fibers can further improve the mechanical properties of bone wax, making the bone wax less likely to break or fracture during plasticity and use, and making the mechanical properties of bone wax relatively stable. At the same time, the PCL / PEG copolymer and modified PLGA fibers are absorbable and degradable materials that can be absorbed by the human body. By regulating the raw material ratio of the PCL / PEG copolymer and PLGA, their degradation rate can be effectively controlled, thereby changing the degradation cycle of bone wax in the human body. PEG can accelerate the degradation cycle of the PCL / PEG copolymer in the human body. PLGA improves the mechanical properties and sealing effect of bone wax in the early stage of hemostasis. As hemostasis is completed, it is first hydrolyzed, which increases the porosity of bone wax and promotes the hydrolysis of the PCL / PEG copolymer. The PCL / PEG copolymer and modified PLGA fibers can be degraded and absorbed by the human body in the later stage of bone healing. The mechanical properties and bonding strength during use and hemostasis are good, and no secondary surgery is required for removal, and they are naturally absorbed with human metabolism.
[0022] 2. In this application, electrospinning is used to prepare PLGA fibers, and reinforcing modifiers are added to the PLGA fibers to improve the mechanical properties of the modified PLGA fibers. At the same time, the reinforcing modifiers are made of degradable and absorbable materials, which further improves the mechanical stability of bone wax without affecting the degradation and absorption of bone wax.
[0023] 3. In this application, regenerated oxidized cellulose and nano-hydroxyapatite are compounded. Regenerated oxidized cellulose can improve the hemostatic performance of bone wax and has an antibacterial effect. The combined use of regenerated oxidized cellulose and nano-hydroxyapatite can improve the hemostatic effect of bone wax while maintaining the strength of the modified PLGA fiber, thereby improving the mechanical strength of bone wax. DETAILED DESCRIPTION
[0024] The present application is further described in detail below with reference to the embodiments.
[0025] Preparation Examples 1-10 of Modified PLGA Fibers Preparation Example 1 The method for preparing modified PLGA fibers comprises the following steps: dissolving PLGA in chloroform with a LA:GA ratio of 70:30 to prepare a spinning solution; adding a reinforcing modifier to the spinning solution in an amount of 11.25 wt %; stirring and shaking the solution to uniformly disperse the reinforcing modifier; and electrospinning the solution at a spinning rate of 0.4 mL / h, a spinning voltage of 1.5 kV, a receiving distance of 15 cm, and a spinning diameter of 0.15 mm to prepare the modified PLGA fibers. The reinforcing modifier comprises regenerated oxidized cellulose and nano-hydroxyapatite in a mass ratio of 1.26:2.15.
[0026] Preparation Example 2 The preparation method of modified PLGA fiber comprises the following steps: dissolving PLGA in chloroform with a LA:GA ratio of 70:30 to prepare a spinning solution; adding a reinforcing modifier to the spinning solution in an amount of 15.35 wt %; stirring and shaking the solution to uniformly disperse the reinforcing modifier; and electrospinning the solution at a spinning rate of 0.4 mL / h, a spinning voltage of 1.5 kV, a receiving distance of 15 cm, and a spinning diameter of 0.3 mm to prepare the modified PLGA fiber. The reinforcing modifier comprises regenerated oxidized cellulose and nano-hydroxyapatite in a mass ratio of 1.35:2.94.
[0027] Preparation Example 3 The difference between Preparation Example 3 and Preparation Example 1 is that in Preparation Example 3, the amount of the reinforcing modifier added to the spinning solution is 5.15 wt %.
[0028] Preparation Example 4 The difference between Preparation Example 4 and Preparation Example 1 is that in Preparation Example 4, the amount of the reinforcing modifier added to the spinning solution is 20.65 wt %.
[0029] Preparation Example 5 The difference between Preparation Example 5 and Preparation Example 1 is that in Preparation Example 5, the reinforcing modifier includes regenerated oxidized cellulose and nano-hydroxyapatite in a mass ratio of 1.26:1.12.
[0030] Preparation Example 6 The difference between Preparation Example 6 and Preparation Example 1 is that in Preparation Example 6, the reinforcing modifier includes regenerated oxidized cellulose and nano-hydroxyapatite in a mass ratio of 1.26:3.02.
[0031] Preparation Example 7 The difference between Preparation Example 7 and Preparation Example 1 is that in Preparation Example 7, an equal amount of regenerated oxidized cellulose is used instead of the reinforcing modifier.
[0032] Preparation Example 8 The difference between Preparation Example 8 and Preparation Example 1 is that in Preparation Example 8, an equal amount of nano-hydroxyapatite is used instead of the reinforcing modifier.
[0033] Preparation Example 9 The difference between Preparation Example 9 and Preparation Example 1 is that in Preparation Example 9, the nanohydroxyapatite is further treated as follows before being added: 1.5 g of nanohydroxyapatite is dispersed in 40 mL of 0.1 mol / L nitric acid solution, ultrasonicated for 30 min, washed, and dried for use; 0.5 mL of KH-550 is mixed with 9 mL of 90% ethanol solution by volume, stirred for 1 h to prepare a mixed solution, the treated nanohydroxyapatite is dispersed in the mixed solution, magnetically stirred at 60 ° C for 6 h, washed, and dried.
[0034] Preparation Example 10 The difference between Preparation Example 10 and Preparation Example 1 is that in Preparation Example 10, the nanohydroxyapatite is further treated as follows before being added: 2 g of nanohydroxyapatite is dispersed in 50 mL of 0.1 mol / L nitric acid solution, ultrasonicated for 30 min, washed, and dried for use; 0.6 mL of KH-550 is mixed with 10 mL of a 90% volume fraction ethanol solution, stirred for 1 h to prepare a mixed solution, the treated nanohydroxyapatite is dispersed in the mixed solution, magnetically stirred at 70°C for 4 h, washed, and dried.
[0035] Preparation Examples 11-12 of PCL / PEG Copolymers Preparation Example 11 The preparation method of PCL / PEG copolymer includes the following steps: 0.4g sodium hydride, 3.25g PEG2000 and 9.98g caprolactone are mixed and stirred until the caprolactone reacts completely, the temperature is raised to 65°C, the mixture is kept warm and stirred for 20 minutes, excess chloroform is added to dissolve the mixture, the mixture is rotary evaporated, ether is added to precipitate, and the mixture is filtered to obtain PCL / PEG copolymer.
[0036] Preparation Example 12 The preparation method of PCL / PEG copolymer includes the following steps: 0.35g sodium hydride, 3.12g PEG2000 and 9.25g caprolactone are mixed and stirred until the caprolactone reacts completely, the temperature is raised to 65°C, the mixture is kept warm and stirred for 20 minutes, excess chloroform is added to dissolve the mixture, the mixture is rotary evaporated, ether is added to precipitate, and the mixture is filtered to obtain PCL / PEG copolymer. Example
[0037] Example 1 An absorbable bone wax comprises the following raw materials in parts by weight: 65 g of a PCL / PEG copolymer, 0.8 g of sodium carboxymethyl cellulose, and 3.25 g of modified PLGA fibers, wherein the PCL / PEG copolymer is the PCL / PEG copolymer prepared in Preparation Example 11, and the modified PLGA fibers are the modified PLGA fibers prepared in Preparation Example 1.
[0038] The preparation method of the absorbable bone wax comprises the following steps: heating the PCL / PEG copolymer to 80°C, adding modified PLGA fibers and stirring until the mixture is uniformly mixed, removing bubbles, placing the mixture in a mold and cooling it to form the absorbable bone wax.
[0039] Example 2 An absorbable bone wax comprises the following raw materials in parts by weight: 75 g of a PCL / PEG copolymer, 1.2 g of sodium carboxymethyl cellulose, and 4.12 g of modified PLGA fibers, wherein the PCL / PEG copolymer is the PCL / PEG copolymer prepared in Preparation Example 12, and the modified PLGA fibers are the modified PLGA fibers prepared in Preparation Example 2.
[0040] The preparation method of the absorbable bone wax comprises the following steps: heating the PCL / PEG copolymer to 70°C, adding modified PLGA fibers and stirring until the mixture is uniformly mixed, removing bubbles, placing the mixture in a mold and cooling it to form the absorbable bone wax.
[0041] Example 3 The difference between Example 3 and Example 1 is that in Example 3, the amount of modified PLGA fiber used is 1.12 g.
[0042] Example 4 The difference between Example 4 and Example 1 is that in Example 4, the amount of modified PLGA fiber used is 8.21 g.
[0043] Example 5 The difference between Example 5 and Example 1 is that in Example 5, the modified PLGA fiber is the modified PLGA fiber prepared in Preparation Example 3.
[0044] Example 6 The difference between Example 6 and Example 1 is that in Example 6, the modified PLGA fiber is the modified PLGA fiber prepared in Preparation Example 4.
[0045] Example 7 The difference between Example 7 and Example 1 is that in Example 7, the modified PLGA fiber is the modified PLGA fiber prepared in Preparation Example 5.
[0046] Example 8 The difference between Example 8 and Example 1 is that in Example 8, the modified PLGA fiber is the modified PLGA fiber prepared in Preparation Example 6.
[0047] Example 9 The difference between Example 9 and Example 1 is that in Example 9, the modified PLGA fiber is the modified PLGA fiber prepared in Preparation Example 7.
[0048] Example 10 The difference between Example 10 and Example 1 is that in Example 10, the modified PLGA fiber is the modified PLGA fiber prepared in Preparation Example 8.
[0049] Example 11 The difference between Example 11 and Example 1 is that in Example 11, the modified PLGA fiber is the modified PLGA fiber prepared in Preparation Example 9.
[0050] Example 12 The difference between Example 12 and Example 1 is that in Example 12, the modified PLGA fiber is the modified PLGA fiber prepared in Preparation Example 10.
[0051] Comparative Example Comparative Example 1 The difference between Comparative Example 1 and Example 1 is that in Comparative Example 1, no modified PLGA fiber is added.
[0052] Performance testing Absorbable bone wax was prepared according to the raw materials and methods of Examples 1-12 and Comparative Example 1, and tested.
[0053] Compression strength: Bone wax was formed into a cylinder with a diameter of 6 mm and a height of 10 mm, cured at room temperature for 24 h, and compressed using a universal testing machine at a compression rate of 1 mm / min. The compression strength was recorded in Table 1.
[0054] Hemostasis and healing test: New Zealand rabbits were anesthetized with 3% sodium pentobarbital solution (1 mL / kg) via the marginal ear vein and placed prone on the operating table with their limbs fixed. A 4-cm sagittal incision was made in the middle of the head, the periosteum was completely peeled off, and the parietal bone was fully exposed. Two circular defects were drilled on either side of the suture of the skull with a 6-mm diameter electric drill. The defects penetrated the parietal bone layer (the bone thickness at the defect was consistent) and did not cross the suture. The defects were randomly assigned to be covered with any of the above samples. Absorbable bone wax was then used to fill the defects. The hemostasis effect of each sample was compared and observed during the operation. The hemostasis time was recorded in Table 1. The periosteum and scalp were sutured with absorbable sutures during the operation. After sterile bandaging, the rabbits were returned to the cage for 12 weeks. After surgery, 40 units of gentamicin were injected intramuscularly daily for 3 consecutive days to prevent infection. The animals were observed daily. Twelve weeks after surgery, the animals were sacrificed by air embolism. Skull specimens extending at least 1.5 cm from the original defect margin, including the adjacent periosteum and dura mater, were obtained. The skull specimens were fixed in 70% alcohol for 24 hours. Bone healing was observed and the results are recorded in Table 1. Excellent healing (a wound healing rate of more than 95%) was designated as Grade I, good healing (a wound healing rate of 85-95%) was designated as Grade II, poor healing (a wound healing rate of 70-85%) was designated as Grade III, and very poor healing (a wound healing rate of less than 70%) was designated as Grade IV.
[0055] Table 1 Absorbable bone wax performance test According to Table 1, Examples 1-2, and Comparative Example 1, it can be seen that the absorbable bone wax prepared in Examples 1-2 has good hemostatic properties and mechanical strength, and after use, it can gradually degrade as the bone wound heals, does not hinder wound healing, and is not prone to symptoms such as inflammation, and has good use effects. The absorbable bone wax of Examples 1-2 includes a PCL / PEG copolymer. The PEG block in the PCL / PEG copolymer effectively increases the hydrophilicity of the copolymer. PCL has good mechanical properties, so that the PCL / PEG copolymer has good mechanical properties while improving hydrophilicity. The absorbable bone wax has good adhesion and better plasticity, and its fit with the bone wound during use is improved, making it less likely to fall off. The improved mechanical properties make it less likely to break or fracture during use, thereby effectively improving the use effect of the absorbable bone wax.
[0056] Modified PLGA fibers are added to the PCL / PEG copolymer, and the modified PLGA fibers can also be absorbed and degraded in the human body. At the same time, the addition of modified PLGA fibers can effectively improve the mechanical strength of absorbable bone wax. The modified PLGA fibers contain regenerated oxidized cellulose with good water absorption properties, which can provide better hemostatic and sealing effects for bone wounds during hemostasis and the early stage of bone healing. At the same time, they assume part of the load-bearing function, which is conducive to the smooth progress of the early stage of bone healing. The degradation rate of PLGA in the modified PLGA fibers is relatively high, which enhances the release of nanohydroxyapatite in the modifier and can promote the middle and late stages of bone healing.
[0057] Compared with Example 1, the compressive strength and healing effect of Example 3-4 decreased, and the hemostasis time of Example 3-4 increased. Example 3-4 changed the amount of modified PLGA fiber added, the amount of modified PLGA fiber added was reduced, the mechanical properties of absorbable bone wax decreased, and the compressive strength decreased, which resulted in poor sealing effect of absorbable bone wax on the wound, prolonged the hemostasis time, and at the same time, the mechanical strength of absorbable bone wax affected the healing process of bone wounds, the sealing effect of absorbable bone wax on the wound decreased, and thus affected the healing effect of bone wounds.
[0058] Compared with Example 1, the compressive strength and healing effect of Example 5-6 decreased, and the hemostasis time of Example 5-6 increased. During the preparation of the modified PLGA fiber used in Example 5-6, the amount of the reinforcing modifier added was changed. The amount of the reinforcing modifier added was reduced, the compressive strength of the bone wax decreased, and the mechanical properties decreased, thereby weakening the sealing effect, thereby increasing the hemostasis time and affecting the healing effect.
[0059] Compared with Example 1, the compressive strength and healing effect of Example 7-10 were decreased, and the hemostasis time was increased. During the preparation of the modified PLGA fibers used in Examples 7-10, the mass ratio of regenerated oxidized cellulose and nano-hydroxyapatite in the reinforcing modifier was changed. In Example 9, only regenerated oxidized cellulose was used, and in Example 10, only nano-hydroxyapatite was used. This shows that the amount of reinforcing modifier added affects the effect of bone wax. At the same time, the mass ratio of regenerated oxidized cellulose and nano-hydroxyapatite affects the strength of the modified PLGA fiber. It can improve the hemostatic effect of bone wax while maintaining the strength of the modified PLGA fiber, thereby improving the mechanical properties of bone wax.
[0060] Compared with Example 1, the compressive strength of Example 11-12 is improved, and the healing effect is better. When preparing the modified PLGA fibers used in Examples 11-12, the nanohydroxyapatite is coated with a silane coupling agent. After the nanohydroxyapatite is coated with the silane coupling agent, the dispersibility of the nanohydroxyapatite in the spinning solution is improved. At the same time, the active groups of the silane coupling agent can be further combined with the regenerated oxidized cellulose and PLGA, thereby improving the bonding strength between PLGA and the reinforcing modifier, which is beneficial to the uniformity and strength of the modified PLGA fibers.
[0061] This specific embodiment is merely an explanation of the present application and is not a limitation of the present application. After reading this specification, those skilled in the art may make non-creative modifications to the present embodiment as needed, but as long as they are within the scope of the claims of the present application, they are protected by the patent law.
Claims
1. An absorbable bone wax, characterized in that: The method comprises the following raw materials in parts by weight: 65-75 parts of PCL / PEG copolymer, 0.8-1.2 parts of sodium carboxymethyl cellulose, and 3.25-4.12 parts of modified PLGA fiber.
2. The absorbable bone wax according to claim 1, wherein: The preparation method of the PCL / PEG copolymer comprises the following steps: mixing sodium hydride, PEG and caprolactone, stirring until the caprolactone reacts completely, heating to 65° C., keeping the mixture warm and stirring for 20 minutes, adding excess chloroform to dissolve the mixture, performing rotary evaporation, adding ether to precipitate the mixture, and filtering the mixture to obtain the PCL / PEG copolymer.
3. The absorbable bone wax according to claim 1, wherein: The preparation method of the modified PLGA fiber comprises the following steps: dissolving PLGA in chloroform to prepare a spinning solution, adding a reinforcing modifier to the spinning solution, stirring and shaking to uniformly disperse the reinforcing modifier, and then performing electrostatic spinning to prepare the modified PLGA fiber.
4. The absorbable bone wax according to claim 1, wherein: The reinforcing modifiers are regenerated oxidized cellulose and nano-hydroxyapatite, and the amount of the reinforcing modifiers added to the spinning solution is 11.25-15.35 wt%.
5. The absorbable bone wax according to claim 4, characterized in that: The mass ratio of the regenerated oxidized cellulose to the nano-hydroxyapatite is (1.26-1.35):(2.15-2.94).
6. The absorbable bone wax according to claim 4, characterized in that: The nano-hydroxyapatite is further processed as follows before being added: the nano-hydroxyapatite is dispersed in a nitric acid solution, ultrasonicated for 30 minutes, washed, dried and set aside; a silane coupling agent is mixed with an ethanol solution, stirred for 1 hour to prepare a mixed solution; the treated nano-hydroxyapatite is dispersed in the mixed solution, magnetically stirred at 60-70°C for 4-6 hours, washed and dried.
7. The absorbable bone wax according to claim 3, characterized in that: The electrospinning conditions are as follows: a spinning rate of 0.4 mL / h, a spinning voltage of 1.5 kV, a receiving distance of 15 cm, and a spinning diameter of 0.15-0.3 mm.
8. The method for preparing absorbable bone wax according to any one of claims 1 to 7, wherein: The following steps are involved: After heating the PCL / PEG copolymer to 70-80°C, the modified PLGA fiber is added and stirred until the mixture is uniform. After removing bubbles, the mixture is placed in a mold and cooled to form, thereby producing absorbable bone wax.